MX342991B - Combinaciones de agentes que disminuyen sap y anticuerpos anti-sap. - Google Patents

Combinaciones de agentes que disminuyen sap y anticuerpos anti-sap.

Info

Publication number
MX342991B
MX342991B MX2009013840A MX2009013840A MX342991B MX 342991 B MX342991 B MX 342991B MX 2009013840 A MX2009013840 A MX 2009013840A MX 2009013840 A MX2009013840 A MX 2009013840A MX 342991 B MX342991 B MX 342991B
Authority
MX
Mexico
Prior art keywords
sap
combinations
antibodies
depleting agents
component
Prior art date
Application number
MX2009013840A
Other languages
English (en)
Other versions
MX2009013840A (es
Inventor
Brian Pepys Mark
Original Assignee
Pentraxin Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentraxin Therapeutics Ltd filed Critical Pentraxin Therapeutics Ltd
Publication of MX2009013840A publication Critical patent/MX2009013840A/es
Publication of MX342991B publication Critical patent/MX342991B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a el uso un compuesto que disminuye de la circulación el componente de amiloide P en suero, en combinación con un anticuerpo específico para el componente de amiloide P en suero, para el tratamiento o profilaxis de amiloidosis.
MX2009013840A 2007-06-27 2008-06-27 Combinaciones de agentes que disminuyen sap y anticuerpos anti-sap. MX342991B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0712503.2A GB0712503D0 (en) 2007-06-27 2007-06-27 Use
PCT/EP2008/058333 WO2009000926A1 (en) 2007-06-27 2008-06-27 Combinations of sap depleting agents and anti-sap antibodies

Publications (2)

Publication Number Publication Date
MX2009013840A MX2009013840A (es) 2013-07-29
MX342991B true MX342991B (es) 2016-10-20

Family

ID=38420831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013840A MX342991B (es) 2007-06-27 2008-06-27 Combinaciones de agentes que disminuyen sap y anticuerpos anti-sap.

Country Status (14)

Country Link
US (2) US7910106B2 (es)
EP (1) EP2173341B1 (es)
JP (1) JP5695903B2 (es)
KR (1) KR101605448B1 (es)
CN (1) CN101801372B (es)
AU (1) AU2008267148B2 (es)
BR (1) BRPI0813655A2 (es)
CA (2) CA2691054C (es)
DK (1) DK2173341T3 (es)
EA (1) EA026959B1 (es)
ES (2) ES2582389T3 (es)
GB (1) GB0712503D0 (es)
MX (1) MX342991B (es)
WO (1) WO2009000926A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
CN103636058A (zh) * 2011-06-24 2014-03-12 汉阳大学校产学协力团 锂空气电池
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
CN105254734A (zh) * 2015-07-16 2016-01-20 中国科学院海洋研究所 一种鱼类血清淀粉样p成分及其应用
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018221649A1 (ja) * 2017-05-31 2018-12-06 協和発酵キリン株式会社 Ａｐｃｓの発現を抑制する核酸
WO2019100039A1 (en) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
US20220071965A1 (en) 2018-12-20 2022-03-10 Pfizer Inc. Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
AU2021368272A1 (en) * 2020-11-02 2023-06-08 Attralus, Inc. Sap fc fusion proteins and methods of use
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
ATE224366T1 (de) * 1997-10-31 2002-10-15 Hoffmann La Roche D-prolinderivate
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ES2318195T3 (es) * 2002-12-23 2009-05-01 William Marsh Rice University Metodos y composiciones para potenciar la formacion de fibrocitos.
WO2004099173A1 (en) * 2003-05-12 2004-11-18 Theracarb Inc. Multivalent inhibitors of serum amyloid p component

Also Published As

Publication number Publication date
US7910106B2 (en) 2011-03-22
JP5695903B2 (ja) 2015-04-08
GB0712503D0 (en) 2007-08-08
AU2008267148A1 (en) 2008-12-31
CA2691054A1 (en) 2008-12-31
JP2010531338A (ja) 2010-09-24
EA201070063A1 (ru) 2010-06-30
AU2008267148B2 (en) 2014-06-12
EP2173341A1 (en) 2010-04-14
US20110166329A1 (en) 2011-07-07
KR20100050495A (ko) 2010-05-13
ES2729648T3 (es) 2019-11-05
KR101605448B1 (ko) 2016-03-22
CA2729034C (en) 2018-10-30
WO2009000926A1 (en) 2008-12-31
CN101801372A (zh) 2010-08-11
US9192668B2 (en) 2015-11-24
DK2173341T3 (en) 2016-07-25
CA2691054C (en) 2017-11-14
CN101801372B (zh) 2014-11-26
US20090191196A1 (en) 2009-07-30
EA026959B1 (ru) 2017-06-30
BRPI0813655A2 (pt) 2014-12-30
EP2173341B1 (en) 2016-06-08
ES2582389T3 (es) 2016-09-12
MX2009013840A (es) 2013-07-29
CA2729034A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
MX2009013840A (es) Combinaciones de agentes que disminuyen sap y anticuerpos.
TW200603828A (en) Treatment of disorders
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
ECSP088529A (es) Anticuerpos anti mn y métodos para su utilización
DK2132228T3 (da) CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
TW200626171A (en) Fixed dosing of HER antibodies
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0816919A2 (pt) Redução de infecções concomitantes em porcos pelo uso de antígeno pcv2.
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MY170509A (en) Activin-actrii antagonists for use in treating anemia
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
IL213523A0 (en) Compositions comprising blood group antigens
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
WO2008150530A3 (en) Cripto binding molecules
WO2006076525A3 (en) Combination cancer therapy with anti-psma antibodies
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
SI2235060T1 (sl) Sredstva za deplecijo b-celic, kot anti-cd20 protitelesa ali njihovi fragmenti za zdravljenje sindroma kronične utrujenosti
WO2012078867A3 (en) Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis

Legal Events

Date Code Title Description
FG Grant or registration